Northwest Investment Counselors LLC Makes New Investment in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Northwest Investment Counselors LLC acquired a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,020 shares of the life sciences company’s stock, valued at approximately $143,000.

A number of other large investors have also made changes to their positions in IART. Cardinal Capital Management lifted its holdings in shares of Integra LifeSciences by 1.6% during the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock valued at $962,000 after acquiring an additional 347 shares during the period. Hexagon Capital Partners LLC lifted its holdings in Integra LifeSciences by 123.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock valued at $29,000 after purchasing an additional 370 shares during the last quarter. Signaturefd LLC boosted its position in Integra LifeSciences by 248.5% in the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after buying an additional 415 shares in the last quarter. Covestor Ltd grew its stake in Integra LifeSciences by 82.5% during the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after buying an additional 921 shares during the last quarter. Finally, Tandem Capital Management Corp ADV increased its holdings in shares of Integra LifeSciences by 2.8% during the fourth quarter. Tandem Capital Management Corp ADV now owns 38,851 shares of the life sciences company’s stock worth $1,692,000 after buying an additional 1,058 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on IART shares. Oppenheimer lowered Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 7th. Citigroup raised their target price on Integra LifeSciences from $24.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, May 22nd. JMP Securities reduced their price target on shares of Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating on the stock in a research report on Tuesday, May 7th. Morgan Stanley decreased their price objective on shares of Integra LifeSciences from $37.00 to $24.00 and set an “underweight” rating on the stock in a report on Tuesday, May 7th. Finally, Truist Financial dropped their target price on shares of Integra LifeSciences from $37.00 to $25.00 and set a “hold” rating for the company in a research note on Tuesday, May 7th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $35.00.

Insider Transactions at Integra LifeSciences

In other news, Chairman Stuart Essig acquired 52,641 shares of Integra LifeSciences stock in a transaction that occurred on Thursday, May 23rd. The shares were acquired at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the purchase, the chairman now directly owns 487,922 shares of the company’s stock, valued at $13,900,897.78. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 3.10% of the company’s stock.

Integra LifeSciences Stock Up 1.1 %

Shares of NASDAQ:IART opened at $29.83 on Tuesday. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35. The stock has a market cap of $2.35 billion, a price-to-earnings ratio of 59.66, a P/E/G ratio of 1.07 and a beta of 1.17. The company has a 50 day moving average of $28.79 and a 200-day moving average of $35.97. Integra LifeSciences Holdings Co. has a one year low of $22.36 and a one year high of $46.75.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, hitting analysts’ consensus estimates of $0.55. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.27%. The firm had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. During the same quarter in the previous year, the business earned $0.74 EPS. The business’s quarterly revenue was down 3.2% compared to the same quarter last year. On average, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 3.03 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.